Sarah J Tabrizi
Sarah J Tabrizi
Professor of Neurology UCL
Verified email at prion.ucl.ac.uk
TitleCited byYear
Huntington's disease: from molecular pathogenesis to clinical treatment
CA Ross, SJ Tabrizi
The Lancet Neurology 10 (1), 83-98, 2011
11092011
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
SJ Tabrizi, DR Langbehn, BR Leavitt, RAC Roos, A Durr, D Craufurd, ...
The Lancet Neurology 8 (9), 791-801, 2009
6932009
Huntington disease: natural history, biomarkers and prospects for therapeutics
CA Ross, EH Aylward, EJ Wild, DR Langbehn, JD Long, JH Warner, ...
Nature Reviews Neurology 10 (4), 204, 2014
5322014
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
SJ Tabrizi, RI Scahill, G Owen, A Durr, BR Leavitt, RA Roos, B Borowsky, ...
The Lancet Neurology 12 (7), 637-649, 2013
5282013
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death
S Gandhi, A Wood-Kaczmar, Z Yao, H Plun-Favreau, E Deas, K Klupsch, ...
Molecular cell 33 (5), 627-638, 2009
5192009
Huntington disease
GP Bates, R Dorsey, JF Gusella, MR Hayden, C Kay, BR Leavitt, M Nance, ...
Nature reviews Disease primers 1, 15005, 2015
5052015
Biochemical abnormalities and excitotoxicity in Huntington's disease brain
SJ Tabrizi, MWJ Cleeter, J Xuereb, JW Taanman, JM Cooper, ...
Annals of Neurology: Official Journal of the American Neurological …, 1999
4671999
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
SJ Tabrizi, RI Scahill, A Durr, RAC Roos, BR Leavitt, R Jones, ...
The Lancet Neurology 10 (1), 31-42, 2011
4592011
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
M Björkqvist, EJ Wild, J Thiele, A Silvestroni, R Andre, N Lahiri, E Raibon, ...
Journal of Experimental Medicine 205 (8), 1869-1877, 2008
4542008
Proteome-based plasma biomarkers for Alzheimer's disease
A Hye, S Lynham, M Thambisetty, M Causevic, J Campbell, HL Byers, ...
Brain 129 (11), 3042-3050, 2006
4542006
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
SJ Tabrizi, R Reilmann, RAC Roos, A Durr, B Leavitt, G Owen, R Jones, ...
The Lancet Neurology 11 (1), 42-53, 2012
3692012
Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
SJ Tabrizi, J Workman, PE Hart, L Mangiarini, A Mahal, G Bates, ...
Annals of neurology 47 (1), 80-86, 2000
3312000
Microglial activation in presymptomatic Huntington's disease gene carriers
YF Tai, N Pavese, A Gerhard, SJ Tabrizi, RA Barker, DJ Brooks, P Piccini
Brain 130 (7), 1759-1766, 2007
3272007
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
A Wood-Kaczmar, S Gandhi, Z Yao, ASY Abramov, EA Miljan, G Keen, ...
PloS one 3 (6), e2455, 2008
3082008
Disease-associated prion protein oligomers inhibit the 26S proteasome
M Kristiansen, P Deriziotis, DE Dimcheff, GS Jackson, H Ovaa, ...
Molecular cell 26 (2), 175-188, 2007
2602007
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population
J Beck, M Poulter, D Hensman, JD Rohrer, CJ Mahoney, G Adamson, ...
The American Journal of Human Genetics 92 (3), 345-353, 2013
2542013
Mitochondria in the etiology and pathogenesis of Parkinson's disease
AHV Schapira, M Gu, JW Taanman, SJ Tabrizi, T Seaton, M Cleeter, ...
Annals of neurology 44 (S1 1), S89-S98, 1998
2531998
Huntington’s disease
MJU Novak, SJ Tabrizi
Bmj 340, c3109, 2010
2502010
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ...
Neurology 78 (10), 690-695, 2012
2392012
Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity
SJ Tabrizi, M Orth, JM Wilkinson, JW Taanman, TT Warner, JM Cooper, ...
Human molecular genetics 9 (18), 2683-2689, 2000
2252000
The system can't perform the operation now. Try again later.
Articles 1–20